SCHEMBL3493341

SCHEMBL3493341

OC[C@@H](O)[C@H](O)COSSOC[C@@H](O)[C@H](O)CO

nearest known ligand 0.50

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
TDP1 Q9NUW8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8394127 0.85 LMNA (0.32) LMNAL3MBTL1TDP1
SCHEMBL319673 0.80
SCHEMBL1270184 0.74 LMNA (0.44) LMNA
SCHEMBL18529337 0.73 LMNA (0.44) LMNAL3MBTL1TDP1
SCHEMBL578416 0.73 LMNA (0.44) LMNAL3MBTL1TDP1
E968 SCHEMBL10956312 0.71 LMNA (0.57) LMNAL3MBTL1TDP1
E968 SCHEMBL10956309 0.71 LMNA (0.57) LMNAL3MBTL1TDP1
E968 SCHEMBL121807 0.71
E968 SCHEMBL2723809 0.71 LMNA (0.67) LMNAL3MBTL1TDP1
E968 SCHEMBL6729753 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100129385-A1 IMMUNOGENIC MOLECULES COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH, THE (AU) 2010-05-27 US disclosed
EP-1861426-A4 IMMUNOGENIC MOLECULES QUEENSLAND INST MED RES (AU) 2008-11-12 EP disclosed
EP-1861426-A1 IMMUNOGENIC MOLECULES THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH (AU) 2007-12-05 EP disclosed
WO-2006084319-A1 IMMUNOGENIC MOLECULES THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH (AU) 2006-08-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100129385-A1 IMMUNOGENIC MOLECULES HLA-DRB1, HLA-C, CD74 LMNA 4700/4885L3MBTL1 4021/4885TDP1 4277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.